tiprankstipranks
Trending News
More News >

JOINN Laboratories Announces Major Financial Product Subscription

Story Highlights
JOINN Laboratories Announces Major Financial Product Subscription

Confident Investing Starts Here:

JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) has issued an update.

JOINN Laboratories has announced a discloseable transaction involving the subscription of RMB440 million in structured deposit products from the Bank of Jiangsu. This move is expected to yield reasonable interest without adversely affecting the company’s financial position, and it highlights JOINN’s strategic financial management aimed at optimizing returns on investments.

The most recent analyst rating on (HK:6127) stock is a Buy with a HK$8.57 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.

More about JOINN Laboratories (China) Co., Ltd. Class H

JOINN Laboratories (China) Co., Ltd. operates in the pharmaceutical and biotechnology industry, focusing on providing preclinical research and development services. The company is involved in the development and testing of pharmaceutical products, contributing to the advancement of medical and health-related innovations.

Average Trading Volume: 4,838,315

Technical Sentiment Signal: Sell

Current Market Cap: HK$12.45B

Learn more about 6127 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1